Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone

Aug 02 2018

• By Jessica Merrill

TEVA

Related Content

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

May 18 2018

Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce

Dec 14 2017

Sandoz's Less Frequently Dosed Copaxone Generic Glatopa Hits Teva Two Months Early

Feb 14 2018

Teva Pushes CGRP Timeline Back To End Of 2018

May 03 2018

Generic Manufacturers Try To Up Their Game As US Pressure Persists

Jun 16 2017

Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle

Oct 04 2017

Related Companies

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

Novartis AG

Novartis AG

Neurocrine Biosciences, Inc.

Amgen, Inc.

Eli Lilly and Company

Additional Topics

Generic Drugs Sales & Earnings Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window